Aptose Biosciences (TSE:APS) Stock Passes Above Fifty Day Moving Average - Here's Why

Key Points

• Aptose Biosciences Inc. shares crossed above their 50-day moving average of C$2.01, trading as high as C$2.19 before settling at C$2.05.
• The company has a significant debt-to-equity ratio of -117.37 and a market capitalization of C$88.27 million.
• Aptose is focused on developing personalized therapies for oncology, with its lead clinical program being a Phase I trial for APTO-253 targeting hematologic malignancies.

Aptose Biosciences Inc. (TSE:APS - Get Free Report) NASDAQ: APTO's share price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of C$2.01 and traded as high as C$2.19. Aptose Biosciences shares last traded at C$2.05, with a volume of 10,614 shares changing hands.

Aptose Biosciences Stock Performance

The company has a debt-to-equity ratio of -117.37, a quick ratio of 5.41 and a current ratio of 1.05. The company has a market cap of C$72.34 million, a P/E ratio of -0.33 and a beta of 1.36. The firm has a 50 day moving average price of C$1.97 and a 200-day moving average price of C$3.98.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.